Volume 9, Issue 2, Pages (February 2008)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 17, Issue 11, Pages (November 2016)

Volume 14, Issue 12, Pages (November 2013)

Volume 370, Issue 9586, Pages (August 2007)

Volume 16, Issue 8, Pages (August 2015)

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm,

Volume 385, Issue 9980, Pages (May 2015)

Volume 13, Issue 2, Pages (February 2012)

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma:

Volume 357, Issue 9273, Pages (June 2001)

Volume 16, Issue 2, Pages (February 2015)

Volume 359, Issue 9323, Pages (June 2002)

Volume 12, Issue 11, Pages (October 2011)

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Volume 11, Issue 4, Pages (April 2012)

Volume 388, Issue 10058, Pages (November 2016)

Volume 378, Issue 9785, Pages (July 2011)

Volume 376, Issue 9734, Pages (July 2010)

Long-term effects of hormone replacement therapy

Suboptimal dosing of rituximab in male and female patients with DLBCL

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD.

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 366, Issue 9482, Pages (July 2005)

Volume 14, Issue 3, Pages (March 2013)

Volume 15, Issue 8, Pages (July 2014)

Volume 392, Issue 10145, Pages (August 2018)

Long-term effects of hormone replacement therapy

Volume 15, Issue 8, Pages (July 2014)

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Volume 12, Issue 9, Pages (September 2013)

Volume 373, Issue 9677, Pages (May 2009)

Volume 15, Issue 4, Pages (April 2014)

Aspirin in the prevention of cancer – Author's reply

Volume 14, Issue 10, Pages (September 2013)

Volume 366, Issue 9482, Pages (July 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Volume 379, Issue 9814, Pages (February 2012)

Volume 375, Issue 9732, Pages (June 2010)

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Volume 378, Issue 9785, Pages (July 2011)

Volume 362, Pages s6-s7 (December 2003)

What would happen if we stopped vaccination?

Volume 6, Issue 6, Pages (June 2005)

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Volume 388, Issue 10058, Pages (November 2016)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 18, Issue 8, Pages (August 2017)

Volume 376, Issue 9757, Pages (December 2010)

Volume 381, Issue 9880, Pages (May 2013)

Volume 14, Issue 6, Pages (May 2013)

Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable.

Volume 375, Issue 9714, Pages (February 2010)

Volume 11, Issue 1, Pages (January 2010)

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Volume 375, Issue 9715, Pages (February 2010)

Volume 14, Issue 9, Pages (August 2013)

Volume 372, Issue 9632, Pages (July 2008)

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.

Stem cell transplantation

Volume 20, Issue 5, Pages (May 2019)

Volume 371, Issue 9611, Pages (February 2008)

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

Presentation transcript:

Volume 9, Issue 2, Pages 105-116 (February 2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Prof Michael Pfreundschuh, MD, Joerg Schubert, MD, Marita Ziepert, Dipl-Math, Rudolf Schmits, MD, Martin Mohren, MD, Eva Lengfelder, MD, Marcel Reiser, MD, Christina Nickenig, MD, Michael Clemens, MD, Norma Peter, MD, Prof Carsten Bokemeyer, MD, Hartmut Eimermacher, MD, Prof Anthony Ho, MD, Martin Hoffmann, MD, Prof Roland Mertelsmann, MD, Prof Lorenz Trümper, MD, Leopold Balleisen, MD, Ruediger Liersch, MD, Bernd Metzner, MD, Frank Hartmann, MD, Bertram Glass, MD, Viola Poeschel, MD, Norbert Schmitz, MD, Prof Christian Ruebe, MD, Prof Alfred C Feller, MD, Prof Markus Loeffler, MD The Lancet Oncology Volume 9, Issue 2, Pages 105-116 (February 2008) DOI: 10.1016/S1470-2045(08)70002-0 Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *On June 14, 2005, when the trial was stopped. The Lancet Oncology 2008 9, 105-116DOI: (10.1016/S1470-2045(08)70002-0) Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 2 Event-free (A), progression-free (B), and overall (C) survival of 1222 elderly patients with aggressive CD20+ B-cell lymphoma treated in the RICOVER-60 trial Patients were assigned to six or eight cycles of CHOP-14 with or without eight cycles of rituximab. 1=6×CHOP-14; 2=8×CHOP-14; 3=6×R-CHOP-14; 4=8×R-CHOP-14. The Lancet Oncology 2008 9, 105-116DOI: (10.1016/S1470-2045(08)70002-0) Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 3 Event-free survival of elderly patients according to International Prognostic Index (IPI) risk group (A) Low-risk patients (6×CHOP-14: n=98; 8×CHOP-14: n=90; 6×R-CHOP-14: n=94; 8×R-CHOP-14: n=90;). (B) Low-intermediate risk patients (6×CHOP-14: n=80; 8×CHOP-14: n=87; 6×R-CHOP-14: n=89; 8×R-CHOP-14: n=83;). (C) High-intermediate risk patients (6×CHOP-14: n=80; 8×CHOP-14: n=78; 6×R-CHOP-14: n=78; 8×R-CHOP-14: n=77). (D) High-risk patients (6×CHOP-14: n=49; 8×CHOP-14: n=50; 6×R-CHOP-14: n=45; 8×R-CHOP-14: n=54). 1=6×CHOP-14. 2=8×CHOP-14. 3=6×R-CHOP-14. 4=8×R-CHOP-14. The Lancet Oncology 2008 9, 105-116DOI: (10.1016/S1470-2045(08)70002-0) Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 4 Event-free survival of patients Patients with complete responses (A), unconfirmed complete responses (B), and partial response (C) after four cycles of CHOP-14 with and without rituximab. 1=6×CHOP-14; 2=8×CHOP-14; 3=6×R-CHOP-14; 4=8×R-CHOP-14. Complete responses (n=261), unconfirmed complete responses (n=276), partial response (n=459). The Lancet Oncology 2008 9, 105-116DOI: (10.1016/S1470-2045(08)70002-0) Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 5 Total doses of cyclophosphamide, adherence to 14-day schedule, and relative dose intensities of cyclophosphamide in the RICOVER-60 trial Blue line=6×CHOP-14. Red line=8×CHOP-14. Green line=6×R-CHOP-14. Purple line=8×R-CHOP-14. The Lancet Oncology 2008 9, 105-116DOI: (10.1016/S1470-2045(08)70002-0) Copyright © 2008 Elsevier Ltd Terms and Conditions